HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Medaka as a model for human nonalcoholic steatohepatitis.

Abstract
The global incidence of nonalcoholic steatohepatitis (NASH) is increasing and current mammalian models of NASH are imperfect. We have developed a NASH model in the ricefish medaka (Oryzias latipes), which is based on feeding the fish a high-fat diet (HFD). Medaka that are fed a HFD (HFD-medaka) exhibited hyperlipidemia and hyperglycemia, and histological examination of the liver revealed ballooning degeneration. The expression of lipogenic genes (SREBP-1c, FAS and ACC1) was increased, whereas the expression of lipolytic genes (PPARA and CPT1) was decreased. With respect to liver fatty acid composition, the concentrations of n-3 polyunsaturated fatty acids (PUFAs) and n-6 PUFAs had declined and the n-3:n-6 ratio was reduced. Treatment of HFD-medaka with the n-3 PUFA eicosapentaenoic acid (EPA) mitigated disease, as judged by the restoration of normal liver fatty acid composition and normal expression levels of lipogenic and lipolytic genes. Moreover, medaka that were fed a diet deficient in n-3 PUFAs developed NASH features. Thus, NASH can be induced in medaka by a HFD, and the proportion of n-3 PUFAs in the liver influences the progress of NASH pathology in these fish. Our model should prove helpful for the dissection of the causes of human NASH and for the design of new and effective therapies.
AuthorsToshihiko Matsumoto, Shuji Terai, Toshiyuki Oishi, Shinya Kuwashiro, Koichi Fujisawa, Naoki Yamamoto, Yusuke Fujita, Yoshihiko Hamamoto, Makoto Furutani-Seiki, Hiroshi Nishina, Isao Sakaida
JournalDisease models & mechanisms (Dis Model Mech) 2010 Jul-Aug Vol. 3 Issue 7-8 Pg. 431-40 ISSN: 1754-8411 [Electronic] England
PMID20371730 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dietary Fats
  • Eicosapentaenoic Acid
Topics
  • Animals
  • Dietary Fats (administration & dosage, pharmacology)
  • Disease Models, Animal
  • Eicosapentaenoic Acid (administration & dosage, pharmacology)
  • Fatty Liver (complications, pathology)
  • Gene Expression Regulation (drug effects)
  • Humans
  • Hyperglycemia (complications, pathology)
  • Hyperlipidemias (complications, pathology)
  • Lipogenesis (drug effects, genetics)
  • Liver (drug effects, pathology)
  • Oryzias (metabolism)
  • Phenotype

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: